CARB-X awards LimmaTech US$6.5 million to advance clinical development of LBT-SA7 LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, announced today that the first participants have been vaccinated in a Phase 1 controlled study of its multivalent vaccine candidate, LBT-SA7. The candidate is designed to prevent skin and soft

Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations in ophthalmology, today announced the pricing of an underwritten offering of 5,000,000 of its ordinary shares, CHF 0.01 nominal value per share, at a price of $20.00 per share, for total gross proceeds of $100 million, before deducting underwriting discounts and

European Union (EU) Horizon Europe and Swiss State Secretariat for Education, Research, and Innovation co-funded NEOLIVER Consortium (total €10M award) is set to develop world’s first autologous bioprinted liver designed for clinical use. Coordinated by University of Utrecht, twelve consortium members will develop technologies to establish an automated manufacturing line, vascularize the biopr

Today, BioVersys (Ticker “BIOV”), a leading Swiss biotech company specializing in novel antibacterial products for serious life-threatening infections, listed its shares at SIX Swiss Exchange. At an opening price of CHF 36.50 per share, the resulting market capitalization of BioVersys was around CHF 216 million.

Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to 225Ac-SSO110 (satoreotide) for the treatment of patients with Small Cell Lung Cancer (SCLC).